At present, diabetes has become one of the most common chronic metabolic diseases, and patients with type 2 diabetes often have glucocorticoids when they are associated with chronic obstructive pulmonary disease, tumor, blood system diseases, kidney diseases, skin diseases, rheumatism and immune diseases. Treatment with glucocordicoids (GC), but the use of GC in patients with diabetes may aggravate the condition of diabetes, worsen blood glucose control and even lead to serious complications, making glucocorticoids more difficult to apply in patients with type 2 diabetes. At present, such patient management is mainly based on the understanding of pharmacology and the personal experience of clinicians, and the current status of blood glucose management is not optimistic.